

Fig.1

10 20 30 40 50
AUCACUCUCUUUAAUCACUACUCACAGUAACCUCAACUCCUGCCACAAUGUACAGGAU

70 80 90 100 110
AACUCCUGUCUUGCAUUUGCACUAAGUCUUGCACUUGCACAAACAGUGCACCUACUUC
ACGTGATT CAGAACGTGAACAGTGTGTC
77-91 92-106

130 140 150 160 170
GUUCUACAAAGAAAACACAGCUACAACUGGAGCAUUUACUGCUGGAUUUACAGAUGAU

190 200 210 220 230
UGAAUGGAAUUAUAAUUAUACAAGAAUCCCAAACUCACCAGGAUGCUCACAUUUAAGUU
ATGTTCTTAGGGTTTGAGTGGTCTACGAGTGTAAATTCAA
198-212 213-227 228-242

250 260 270 280 290
ACAUGCCCAAGAAGGCCACAGAACUGAAACAUCUUCAGUGUCUAGAAGAAGAACUCA
TGTACGGGTTCTTCCGGTCTTCTTGAGTT
243-257 287-301

310 320 330 340 350
CUCUGGAGGAAGUGCUAAAUUUAGCUCAAAGCAAAACUUUCACUUAAGACCCAGGGA
GAGACCTCCTT CACGAGTGAATTCTGGGTCCCT
302-316 342-356

370 380 390 400 410
UAAUCAGCAAUAUCAACGUAAUAGUUCUGGAACUAAAGGGAUCUGAAACAACAUUCAU
ATTAGTCGTTA
357-371

430 440 450 460 470
GUGAAUAUGCUGAUGAGACAGCAACCAUUGUAGAAUUUCUGAACAGAUGGAUUACCUU

490 500 510 520 530
GUCAAAGCAUCAUCUCAACACUAACUUGAUAAUUAAGUGCUUCCCAUUA AAAACAUAU

550 560 570 580 590 600
GGCCUUCUAUUUAUUUAAUAAUUAUUUUAUUUUAUUUUAUUGUUGAAUGUAUGGUUUGCUA

610 620 630 640 650 660
CCUAUUGUAACUAUUUAUUCUUAACUUA AAAACUAUAAUUAUGGAUCUUUUAUGAUUCUUL

670 680 690 700 710 720
UUGUAAGCCCUAGGGGCUCUAAA AUGGUUUCACUUAUUUAUCCCAAAUUAUUUAUUUU

730 740 750 760 770 780
UGUUGAAUGUUA AAUAUAGUAUCUAUGUAGAUUGGUUAGUAAACUAUUUAUAAAUUU

790 800
AUAAAUUAAAAAAAAAAAAAC

Fig.2

10 20 30 40 50 60
GAUCGUUAGCUUCUCCUGAUAAACUAAUUGCCUCACAUUGUCACUGCAAUUCGACACCUA

70 80 90 100 110 120
UUAUUGGGUCUACCUCCCAACUGCUUCCCCUCUGUUCUUCUCCUGCUAGCAUGUGCCGGC
GAGTGGAGGGTTGAC GAAGGGGGAGACAAG CG

70-84 85-99

130 140 150 160 170 180
AACUUUGUCCACGGACACAAGUGCGAUUACCUUACAGGAGAUCAUCAAACUUUGAAC
TTGAAACAGGTGC CTGTGTTACGCTAT ACTTG

119-133 134-148

190 200 210 220 230 240
AGCCUCACAGAGCAGAAGACUCUGUGCACCAGUUGACCGUAACAGACAUCUUUGCUGCC
TCGGAGTGTC TCGTCTTCTGAGACA

176-190 191-205

250 260 270 280 290 300
UCCAAGAACACAACUGAGAAGGAAACCUUCUGCAGGGCUGCGACUGUGCUCCGGCAGUUC
TGAAGACGTCCCGA CGCTGACACGAGGCC

265-279 280-294

310 320 330 340 350 360
UACAGCCACCAUGAGAAGGACACUCGCUGCCUGGGUGCGACUGCACAGCAGUUCCACAGG

370 380 390 400 410 420
CACAAGCAGCUGAUCCGAUUCUGAAACGGCUCGACAGGAACCUCUGGGGCCUGGCGGGC
GCTAAGGACTTTGCC GAGCTGTCCTTGGAG

376-390 391-405

430 440 450 460 470 480
UUGAAUUCUGUCCUGUGAAGGAAGCCAACCAGAGUACGUUGGAAAACUUCUUGGAAAGG

490 500 510 520 530 540
CUAAAGACGAUCAUGAGAGAGAAUUAUCAAAGUGUUCGAGCUGAAUUAUUUAUUUAUG

550 560 570 580 590 600
AGUUUUUGAUAGCUUUUUUUUAAGUAUUUAUUAUUUAUAACUCAUCAUAAAAUAAAG

610
UAUAUAUAGAAUCUAAAA

Fig.3




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8




Fig.9




Fig.10




Fig.11




Fig.12




Fig.13

IL-2 342-356




Fig.14

IL-2 357-371




Fig.15

IL-4 119-133




Fig.16

IL-4 134-148




Fig.17

IL-4 265-279




Fig.18

IL-4 280-294





Fig.19



¹ Time after adding 10 nM PMA, 0.5 mg/ml anti-human CD3 antibody and anti-human CD28 antibody to cultured Jurkat E6-1 cells

² The concentration of IL-2 in the culture supernatants measured by ELISA using anti-human IL-2 antibody

^{3, 4} Determination of cellular IL-2 expression level by dot blotting using RNA probe complementary to human IL-2 mRNA

Fig.20

DIG-11-dUTP & Reverse transcriptase	Oligonucleotide	IL-2 expression	
		(+)	(-)
none	none		
none	none		
added	oligo dA		
added	oligo dT		

Fig.21

PROBE	IL-2 EXPRESSION		
	(+)	(-)	
IL-2 228-242(D)			
IL-2 243-257(A)			
IL-2 198-212(D)			
IL-2 213-227(A)			
IL-2 77-91(D)			
IL-2 92-106(A)			
IL-2 287-301(D)			
IL-2 302-316(A)			
IL-2 342-356(D)			
IL-2 357-371(A)			
NONE			

Fig.22




Fig.23

PROBE	IL-2 EXPRESSION					
	(+)			(-)		
IL-2 228-242(D) & IL-2 243-257(A)	D/A	A/A	D/D	D/A	A/A	D/D
IL-2 198-212(D) & IL-2 213-227(A)						
IL-2 77-91(D) & IL-2 92-106(A)						
IL-2 287-301(D) & IL-2 302-316(A)						
IL-2 342-356(D) & IL-2 357-371(A)						
NONE & NONE						

Fig.24




Fig.25




Fig.26




Fig.27




Fig.28




Fig.29




Fig.30




Fig.31




Fig.32




Fig.33




Fig.34




Fig.35




Fig.36




Fig.37




Fig.38




Fig.39




Fig.40





Fig.41



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.42




Fig.43




Fig.44




Fig.45





Fig.46



IL-2 mRNA (+); 48/48

[illegible]

Fig.48

IL-2 mRNA (+); 9/9

Fig.49

IL-2 mRNA (+); 0/32

Fig.50

IL-2 mRNA (+); 18/35



Title: Method For Selectively Separating Live Cells Expressing A Specific Gene

Inventors: ISHIBASHI et al.

Atty Docket No.: 400684/SOEI

Leydig, Voit & Mayer, Ltd.

202-737-6770

Fig.51

IL-2 mRNA (+); 7/7



Fig.52

IL-2 mRNA (+); 8/39



Fig.53

IL-2 mRNA (+); 8/8



Fig.54




Fig.55




Fig.56




Fig.57




Fig.58




Fig.59




Fig.60




Fig.61




Fig.62




Fig.63




Fig.64




Fig.65




Fig.66




Fig.67




Fig.68




Fig.69




Fig.70




Fig.71




Fig.72




Fig.73




Fig.74




Fig.75




Fig.76




Fig.77




Fig.78




Fig.79




Fig.80




Fig.81




Fig.82




Fig.83




Fig.84




Fig.85




Fig.86




Fig. 87

IL-2 mRNA (+); 11/11	γ -IF mRNA (+); 14/14	TNF- β mRNA (+); 11/11
IL-4 mRNA (+); 0/10	IL-5 mRNA (+); 0/11	IL-10 mRNA (+); 0/9

Fig.88




Fig. 89

IL-2 mRNA (+); 0/11	γ -IF mRNA (+); 0/11	TNF- β mRNA (+); 0/9
IL-4 mRNA (+); 12/12	IL-5 mRNA (+); 11/11	IL-10 mRNA (+); 11/11

Fig.90




Fig.91

IL-2 mRNA (+); 10/10	γ -IF mRNA (+); 9/9	TNF- β mRNA (+); 9/9
IL-4 mRNA (+); 0/9	IL-5 mRNA (+); 0/8	IL-10 mRNA (+); 0/9

Fig.92




Fig.93

IL-2 mRNA (+); 0/7	γ -IF mRNA (+); 0/8	TNF- β mRNA (+); 0/8
IL-4 mRNA (+); 9/9	IL-5 mRNA (+); 10/10	IL-10 mRNA (+); 9/9

Fig.94

